Lipid nanoparticle-mediated drug delivery to the brain

Enhancing paracellular and transcellular permeability using nanotechnological approaches for the treatment of brain and retinal diseases

“…Several review articles are also devoted to the use of lipid-based nanoparticles for the delivery of drugs to the brain underlining the strong focus on these structures for drug delivery. 44,45 Scalable manufacturing of LNPs has been achieved lately and played an important part in the large-scale provision of the COVID-19 mRNA vaccine for systemic administration via intramuscular injection. While low encapsulation efficiency and rapid leaking were pendulous issues for the liposomal delivery of many amphipathic basic drugs, doxorubicin was encapsulated into unilamellar vesicles with over 90% trapping efficiency using the concept of drug diffusion driven by a pH gradient across the lipid membranes for drug loading.…”

Ionic liquids revolutionizing biomedicine: recent advances and emerging opportunities

“…For example, Hamadani et al developed a protein-avoidant IL strategy to modify nanoparticles for increasing bloodstream circulation and driving biodistribution. 288,289 Compared with PEG modification with the risk of developing anti-PEG antibodies, the introduction of an IL (choline hexenoate) endowed the nanoparticles with negative charge and a larger hydrodynamic radius, resulting in diminished protein adsorption and reduced liver biodistribution. 288 In addition, choline hexenoate could also be used to electrostatically solvate copolymers by direct dissolution, form stable drug carriers, reduce hemolysis, and imbue the ability of hitchhiking onto red blood cells.…”

Virus-Inspired Glucose and Polydopamine (GPDA)-Coating as an Effective Strategy for the Construction of Brain Delivery Platforms

“…Central nervous system (CNS) disorders pose a significant burden on human health and well-being. − The therapy of CNS disorders is compromised by the presence of the blood–brain barrier (BBB), which severely inhibits the transport of therapeutic drugs to the brain. , Most small-molecule drugs and almost all macromolecular drugs cannot cross BBB. Given these limitations, nanoparticles have been explored as vehicles to improve drug delivery into the brain. − Numerous nanocarriers have been developed to enhance the transport of drugs across the BBB through various mechanisms ,− including receptor-mediated transport (RMT), adsorption-mediated transport (AMT), and carrier-mediated transport (CMT).…”